Quality control (QC) of biospecimens from oral and maxillofacial tumors patients constitutes a critical foundation for the prevention, diagnosis, treatment, and precision medicine research of these diseases. Biospecimen quality directly governs the discovery and validation of disease biomarkers, the elucidation of pathogenesis, and the efficacy of clinical translation. QC spans the entire biospecimen lifecycle—encompassing collection, processing, storage, transportation, and utilization. Its primary objectives are to ensure sample integrity, reliability, traceability, and consistency, thereby guaranteeing the robustness of research data; the accuracy of molecular subtyping, biomarker identification, and treatment response prediction; and the precision of clinical decision-making. However, current QC frameworks for these biospecimens remain underdeveloped. Drawing on domestic and international technical standards, regulatory guidelines, and recent research advances, this paper elaborates on the importance of implementing a QC management system throughout the biospecimen lifecycle. It focuses on QC methodologies tailored to diverse biospecimen types, examining how standardized sampling procedures, regulated preprocessing workflows, and optimized long-term storage conditions influence sample quality. We aim to provide concrete guidance and a transferable paradigm for establishing standardized QC protocols and an informatics-enabled traceability system specific to oral and maxillofacial tumors. Such efforts are intended to enhance the research value and clinical utility of these biospecimens, furnishing reliable sample resources and technical support for the development of precision diagnostics and therapeutics. Furthermore, we advocate for a dual-track “QC plus Ethics” management framework within biobanks. This approach would reinforce ethical and legal safeguards, establishing a robust barrier to support safe scientific innovation and clinical translation.

【Objective】 To analyze the literature on the relationship between gut microbiota and bone metabolism, identify the current research hotspots and difficulties, and provide research ideas and directions for the clinical prevention and treatment of bone metabolism related diseases. 【Methods】 Based on the Citespace literature visualization analysis software, the co-occurrence and cluster analysis of keywords and other information of the included 394 literatures were performed, and the visual map was drawn. 【Results】 Among the included literatures, the keywords such as inflammatory bowel disease, T cells, dendritic cells, short-chain fatty acids, and chronic kidney disease appeared with high frequency. The cluster of intestinal alkaline phosphatase, metabolic osteoarthritis, dendritic cells, and signaling pathway was the current research hotspot. Recent years have witnessed a rapid increase in published articles in this field, with the United States as the leading origin. 【Conclusion】 The mechanism by which gut microbiota interferes with the immune system and regulates bone metabolism to maintain bone homeostasis is still the core of current research.

Objective To evaluate the efficacy of TCM Bufei Yishen method combined with conventional western medicine for patients with stable chronic obstructive pulmonary disease (COPD) presenting lung-kidney deficiency.Methods Sixty six COPD patients with lung-kidney deficiency admitted from January 2014 to December 2015 were randomly divided into Bufei Yishen (BY) group (n=34) and control group (n=32).Patients in control group treated with conventional western medicine and those in BY group were treated with TCM Bufei Yishen recipe combined with conventional western medicine.The pulmonary function and COPD Assessment Test (CAT) score were evaluated before and after treatment,and after 3 month-following up.Results In BY group the pulmonary function parameters FEV1 and FEV1/FVC after treatment were significantly higher than those before treatment (69.91±8.15 vs.51.56 ± 8.33,t=4.435,P< 0.01;57.33 ± 9.86 vs.49.89 ± 8.89,t=3.526,P<0.05,respectively);the FEV1 and FEV1/FVC after 3-momth follow up were significantly higher than those before treatment (65.68±9.54 vs.51.56±8.33,t=3.993,P<0.05;59.08±8.49 vs.49.89±8.89,t=3.668,P<0.05,respectively).In control group the FEV1 and FEV1/FVC after 3-momth follow up were significantly higher than those before treatment (63.94±8.76 vs.50.98±8.08,t=4.475,P<0.05;59.12±9.55 vs.50.35±9.06,t=3.614,P<0.05,respectively).The pulmonary function parameters FEV1 of BY group was significantly better than that of control group (69.91±8.15 vs.62.02±8.91,t=3.745,P<0.05) after 3-months of follow-up.After treatment,the CAT score in both group was decreased (BY group: 27.35±2.93 vs.30.36±3.19,t=3.548,P<0.05;control group: 29.06±2.67 vs.30.51±2.99,t=1.832,P<0.05);however,the CAT score was decreased more markedly in BY group than that in control group (t=2.658,P<0.05).Conclusion TCM Bufei Yishen method combined with conventional western medicine can improve the pulmonary function and quality of life of patients with stable COPD presenting lung-kidney deficiency.

Due to the complexity of proteome samples, comprehensive analysis to characterize all proteins was still not possible with present methodologies. It has been shown that replicate runs could increase the number of identified) proteins. However, the redundancy of protein identifications was high. High-abundant peptides tended to be analyzed repeatedly in different runs. To reduce the redundancy and improve the efficiency of identification), we studied the MS/MS acquisition method of linear ion trap Fourier transform ion cyclotron resonance)-mass spectrometry(LTQ-FT) and an acquisition strategy based on exclusion of precursor ions was developed). It proved that the strategy could extremely reduce the redundancy of MS/MS acquisition and improve) the efficiency of protein identifications.